
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
The FDA has received a new drug application from ALZA Corp. for dapoxetine hydrochloride, a possible new treatment for premature ejaculation.





